PEDIATRIC DRUG STUDY INCENTIVES UNDER REVISED KASSEBAUM BILL
Executive Summary
PEDIATRIC DRUG STUDY INCENTIVES UNDER REVISED KASSEBAUM BILL would be available to companies that study allergy and asthma drugs in children, as well as to those studying drugs that do not routinely bear pediatric indications. Revised from a version that was introduced at the end of the previous Congress, the bill (S 2010) introduced by Sen. Kassebaum (R-Kans.) April 12 removes the restrictions on the application of the incentives that were contained in the earlier draft. Kassebaum deleted the class exclusion for allergy and asthma drugs in response to suggestions that pediatric studies of such drugs are not sufficient.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth